| Original language | English (US) |
|---|---|
| Pages (from-to) | 1335-1337.e3 |
| Journal | Journal of Allergy and Clinical Immunology: In Practice |
| Volume | 7 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2019 |
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 7, No. 4, 04.2019, p. 1335-1337.e3.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Predictors of inhaled corticosteroid taper failure in adults with asthma
AU - National Heart, Lung, and Blood Institute Asthmanet
AU - Cardet, Juan Carlos
AU - Codispoti, Christopher D.
AU - King, Tonya
AU - Bacharier, Leonard
AU - Carr, Tara
AU - Castro, Mario
AU - Chinchilli, Vernon
AU - Dunn, Ryan
AU - Holquing, Fernando
AU - Engle, Linda
AU - Nelson, Kyle
AU - Ortega, Victor E.
AU - Peters, Michael
AU - Ramratnam, Sima
AU - Krishnan, Jerry A.
AU - Wechsler, Michael E.
AU - Israel, Elliot
N1 - Funding Information: This study was supported by the National Heart, Lung, and Blood Institute (grant nos. HL098102 , U10HL098096 , UL1TR000150 , UL1TR000430 , UL1TR000050 , HL098075 , UL1TR001082 , HL098090 , HL098177 , UL1TR000439 , HL098098 , UL1TR000448 , HL098107 , HL098112 , HL098103 , UL1TR000454 , and HL098115 ). Funding Information: This study was supported by the National Heart, Lung, and Blood Institute (grant nos. HL098102, U10HL098096, UL1TR000150, UL1TR000430, UL1TR000050, HL098075, UL1TR001082, HL098090, HL098177, UL1TR000439, HL098098, UL1TR000448, HL098107, HL098112, HL098103, UL1TR000454, and HL098115).Conflicts of interest: J. C. Cardet reports grant support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) (K23AI125785) during the conduct of the study. T. S. King reports grants from the National Heart, Lung, and Blood Institute (NHLBI) during the conduct of the study. L. Bacharier reports grants from the National Institutes of Health (NIH)/NHLBI during the conduct of the study and personal fees from GlaxoSmithKline, Genentech/Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi, Vectura, and Circassia, outside the submitted work. T. Carr reports grants from NIH-NHLBI AsthmaNet during the conduct of the study and personal fees from AstraZeneca and Regeneron, outside the submitted work. M. Castro reports grants from the NIH and the American Lung Association during the conduct of the study; personal fees from Aviragen, Boehringer Ingelheim, Boston Scientific, Elsevier, Genentech, GSK, Holaira, and Teva; and grants from Amgen, Boehringer Ingelheim, Genentech, Gilead, GSK, Invion, MedImmune, Sanofi-Aventis, and Vectura, all outside the submitted work. V. Chinchilli reports grants from the NHLBI during the conduct of the study. L. Engle reports grants from the NIH-NHLBI during the conduct of the study. M. Peters reports personal fees from Merck and Genentech, outside the submitted work. J. A. Krishnan reports grants from the Patient-Centered Outcomes Research Institute and the NIH, outside the submitted work. M. E. Wechsler reports personal fees from AstraZeneca, Vectura, Regeneron, Meda, Mylan, Gilacure, Tunitas, Genentech, Theravance, Neurotronic, Sentien, Teva, Boehringer Ingelheim, BSCI, and Novartis and grants and personal fees from Sanofi and GlaxoSmithKline, outside the submitted work. E. Israel reports personal fees from AstraZeneca, Pneuma Respiratory, Sanofi, Merck, Entrinsic Health Solutions, GlaxoSmithKline, Philips Respironics, Bird Rock Bio, Nuvelution Pharmaceuticals, Vitaeris, Inc, and Regeneron Pharmaceuticals; personal fees and other fees from Novartis and Teva Specialty Pharmaceuticals; other fees from Research in Real Life and Vorso Corp.; grants from Genentech, Sanofi, and Boehringer Ingelheim; and nonfinancial support from Boehringer Ingelheim, GlaxoSmithKline, Merck, Sunovion, Teva, and Teva Specialty Pharmaceuticals, outside the submitted work. This study was supported by the National Heart, Lung, and Blood Institute (grant nos. HL098102, U10HL098096, UL1TR000150, UL1TR000430, UL1TR000050, HL098075, UL1TR001082, HL098090, HL098177, UL1TR000439, HL098098, UL1TR000448, HL098107, HL098112, HL098103, UL1TR000454, and HL098115). Conflicts of interest: J. C. Cardet reports grant support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) (K23AI125785) during the conduct of the study. T. S. King reports grants from the National Heart, Lung, and Blood Institute (NHLBI) during the conduct of the study. L. Bacharier reports grants from the National Institutes of Health (NIH)/NHLBI during the conduct of the study and personal fees from GlaxoSmithKline, Genentech/Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi, Vectura, and Circassia, outside the submitted work. T. Carr reports grants from NIH-NHLBI AsthmaNet during the conduct of the study and personal fees from AstraZeneca and Regeneron, outside the submitted work. M. Castro reports grants from the NIH and the American Lung Association during the conduct of the study; personal fees from Aviragen, Boehringer Ingelheim, Boston Scientific, Elsevier, Genentech, GSK, Holaira, and Teva; and grants from Amgen, Boehringer Ingelheim, Genentech, Gilead, GSK, Invion, MedImmune, Sanofi-Aventis, and Vectura, all outside the submitted work. V. Chinchilli reports grants from the NHLBI during the conduct of the study. L. Engle reports grants from the NIH-NHLBI during the conduct of the study. M. Peters reports personal fees from Merck and Genentech, outside the submitted work. J. A. Krishnan reports grants from the Patient-Centered Outcomes Research Institute and the NIH, outside the submitted work. M. E. Wechsler reports personal fees from AstraZeneca, Vectura, Regeneron, Meda, Mylan, Gilacure, Tunitas, Genentech, Theravance, Neurotronic, Sentien, Teva, Boehringer Ingelheim, BSCI, and Novartis and grants and personal fees from Sanofi and GlaxoSmithKline, outside the submitted work. E. Israel reports personal fees from AstraZeneca, Pneuma Respiratory, Sanofi, Merck, Entrinsic Health Solutions, GlaxoSmithKline, Philips Respironics, Bird Rock Bio, Nuvelution Pharmaceuticals, Vitaeris, Inc, and Regeneron Pharmaceuticals; personal fees and other fees from Novartis and Teva Specialty Pharmaceuticals; other fees from Research in Real Life and Vorso Corp.; grants from Genentech, Sanofi, and Boehringer Ingelheim; and nonfinancial support from Boehringer Ingelheim, GlaxoSmithKline, Merck, Sunovion, Teva, and Teva Specialty Pharmaceuticals, outside the submitted work. Funding Information: Conflicts of interest: J. C. Cardet reports grant support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) (K23AI125785) during the conduct of the study. T. S. King reports grants from the National Heart, Lung, and Blood Institute (NHLBI) during the conduct of the study. L. Bacharier reports grants from the National Institutes of Health (NIH)/NHLBI during the conduct of the study and personal fees from GlaxoSmithKline, Genentech/Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi, Vectura, and Circassia, outside the submitted work. T. Carr reports grants from NIH-NHLBI AsthmaNet during the conduct of the study and personal fees from AstraZeneca and Regeneron, outside the submitted work. M. Castro reports grants from the NIH and the American Lung Association during the conduct of the study; personal fees from Aviragen, Boehringer Ingelheim, Boston Scientific, Elsevier, Genentech, GSK, Holaira, and Teva; and grants from Amgen, Boehringer Ingelheim, Genentech, Gilead, GSK, Invion, MedImmune, Sanofi-Aventis, and Vectura, all outside the submitted work. V. Chinchilli reports grants from the NHLBI during the conduct of the study. L. Engle reports grants from the NIH-NHLBI during the conduct of the study. M. Peters reports personal fees from Merck and Genentech, outside the submitted work. J. A. Krishnan reports grants from the Patient-Centered Outcomes Research Institute and the NIH, outside the submitted work. M. E. Wechsler reports personal fees from AstraZeneca, Vectura, Regeneron, Meda, Mylan, Gilacure, Tunitas, Genentech, Theravance, Neurotronic, Sentien, Teva, Boehringer Ingelheim, BSCI, and Novartis and grants and personal fees from Sanofi and GlaxoSmithKline, outside the submitted work. E. Israel reports personal fees from AstraZeneca, Pneuma Respiratory, Sanofi, Merck, Entrinsic Health Solutions, GlaxoSmithKline, Philips Respironics, Bird Rock Bio, Nuvelution Pharmaceuticals, Vitaeris, Inc, and Regeneron Pharmaceuticals; personal fees and other fees from Novartis and Teva Specialty Pharmaceuticals; other fees from Research in Real Life and Vorso Corp.; grants from Genentech, Sanofi, and Boehringer Ingelheim; and nonfinancial support from Boehringer Ingelheim, GlaxoSmithKline, Merck, Sunovion, Teva, and Teva Specialty Pharmaceuticals, outside the submitted work.
PY - 2019/4
Y1 - 2019/4
UR - http://www.scopus.com/inward/record.url?scp=85054093362&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054093362&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2018.05.039
DO - 10.1016/j.jaip.2018.05.039
M3 - Article
C2 - 30240889
AN - SCOPUS:85054093362
SN - 2213-2198
VL - 7
SP - 1335-1337.e3
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 4
ER -